Well, for starters Biden ain't the one producing it.
Secondly, there is the issue of logistics (space, technology, personel, etc.) for Regeneron to ramp up.
I suspect this may have played a role:
Manufacturing shift to Ireland frees up US capacity for Regeneron’s COVID antibodies
Who says...